A Gut Drug Pulls Refractory Ulcerative Colitis Patients Back Into Remission

Ulcerative colitis (UC) is a chronic autoimmune condition that causes inflammation and ulcers in the lining of the colon, leading to abdominal pain, urgency, and bloody diarrhea that can be debilitating during flares. While there are several biologic and oral treatments available, a meaningful share of patients either don't respond adequately to their first treatment or lose response over time, leaving them in a genuinely difficult, refractory category with fewer remaining options.

Obefazimod, an investigational oral pill made by the French biotech Abivax, works differently from most existing UC treatments. Rather than targeting a single inflammatory protein directly, it works through a novel microRNA pathway (specifically miR-124) that helps dial down several inflammatory signals at once. Abivax has been running a large Phase 3 program called ABTECT to test the drug across different UC patient populations, including a maintenance study of 580 patients that reported strong primary results in early June, with both the 25mg and 50mg doses producing clinical remission rates around 51% at week 44, compared with just 10.4% on placebo.

What's new, and arguably more clinically important, comes from the Part 2 results Abivax announced on June 29, 2026. This portion of the trial specifically looked at patients who hadn't responded during the initial treatment phase, exactly the harder-to-treat group doctors most need better options for. Among these induction non-responders, 37.2% still went on to reach clinical remission by week 44, and 34.5% reached endoscopic remission, meaning the actual lining of the colon looked healed, not just symptoms improving. Patients who had responded initially but then relapsed were able to regain remission at a 45.5% rate once their dose was increased.

Safety data across both parts of the 44-week maintenance trial showed no new safety signals, which matters for a drug patients would likely take long-term. Abivax says the combined maintenance data supports its plan to file a New Drug Application with the FDA in the fourth quarter of 2026, which would put obefazimod on a realistic path toward approval sometime in 2027 if that filing goes smoothly.

For UC patients who've cycled through biologics without lasting relief, this data matters less because it's a brand-new mechanism and more because it specifically shows benefit in exactly the group that's hardest to help, those who didn't respond the first time. It's still an investigational drug, not yet available outside of clinical trials, but it's one worth watching and worth asking your gastroenterologist about as it moves through the approval process.